PDCD1 and melanoma: In one study, including 68 patients with advanced melanoma treated with anti-CTLA-4 or anti-PD-1, the median level of circulating DNT decreased, while CD4+ and NK cells increased in patients who responded to treatment compared to those who did not [97].